Biowaiver

In vivo bioavailability and/or bioequivalence investigations may be waived with a Biowaiver (not considered necessary for product approval). A dissolution test could be used as a surrogate basis for determining whether two medicinal items are equal instead of expensive and time-consuming in vivo trials. At the time, the Biowaiver was only used for pharmaceutical scale-up and post-approval adjustments (SUPAC).

  • High Solubility. High Permeability
  • Low solubility. High Permeability
  • High Solubility. Low Permeability
  • Low Solubility. Low Permeability

Related Conference of Biowaiver

October 23-24, 2025

21st Annual Meet on Pharmaceutical Sciences

Paris, France
November 11-12, 2025

6th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
November 13-14, 2025

21st International Conference on Pharmaceutical Chemistry

Aix-en-Provence, France
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Paris, France
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 01-02, 2025

13th International Conference on Clinical Trials

Vancouver, Canada
December 30-31, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, UK
March 23-24, 2026

36th Annual European Pharma Congress

London, UK
April 16-17, 2026

19th European Biosimilars Congress

Rome, Italy
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands
May 28-29, 2026

3rd International Conference on Pharmacognosy

Madrid, Spain
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy

Biowaiver Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in